Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Potentia commences clinical trials for AMD drug
POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular
POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular
The last of three phase III trials evaluating Corlux for treating the psychotic features of psychotic major depression (PMD), did not achieve statistical significance compared to placebo. However,
The trial is the fourth and final planned multi-center study in the company’s phase III development program for ferumoxytol, an intravenous iron replacement therapeutic for the treatment of
In collaboration with cancer scientists, UBC stem cell researchers found that a protein called podocalyxin – which the researchers had previously shown to be a predictor of metastatic
Benign prostatic hyperplasia (BPH) afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated
Lialda is the first and only FDA-approved once daily oral formulation of mesalamine, and is available in dosages of 2.4 g/day and 4.8 g/day, allowing patients to take
The licensed technology potentially allows for the more efficient triggering of RNA interference (RNAi) and includes the use of shRNAis either delivered as RNA compositions or encoded by
The two-year-old boy from Indiana inadvertently contracted eczema vaccinatum from his father, a US soldier who had been deployed to Iraq, when he came into contact with the
The trial enrolled 423 patients across sites in both the US and Brazil. The primary endpoint of the study was antipsychotic efficacy as measured after day 42 compared
Vascugel is a novel allogeneic cell therapy product that restores natural repair and regeneration pathways in the vasculature. The upcoming phase II studies are to evaluate the continued